1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


Delayed Nasdaq  -  04:00 2022-08-18 pm EDT
147.61 USD   -2.91%
08/17European ADRs Move Lower in Wednesday Trading
08/17The market got ahead of itself on retailers' earnings
08/17The market got ahead of itself on retailers' earnings
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

University of Pennsylvania : University of Pennsylvania's first NFT commemorates mRNA research; Proceeds from the July auction of the non-fungible token-a digital asset-will benefit ongoing research at Penn

06/22/2022 | 06:20am EDT

The historic scientific breakthrough at the Perelman School of Medicine at the University of Pennsylvania that helped lead the world's fight against COVID-19 through mRNA-based vaccines is being commemorated through a non-fungible token-a digital asset to be auctioned by Christie's-that will support ongoing research at Penn.

The University of Pennsylvania mRNA NFT: Vaccines for a New Era is a one-of-a-kind digital artifact designed by Penn and Drew Weissman, the Roberts Family Professor in Vaccine Research, who, with scientific collaborator Katalin Kariko, an adjunct professor of neurosurgery at Penn and a senior vice president at BioNTech, pioneered the foundational mRNA modification technology that plays a critical role in both the Pfizer/BioNTech and Moderna vaccines for COVID-19 that have impacted billions of people globally.

Twenty-five years ago, Drew Weissman and Katalin Kariko struck up their first conversations at Penn by a copy machine, where both were printing journal articles. That chance encounter laid the foundation for a revolution in mRNA technology, innovations that are now being leveraged to confront a host of biomedical challenges. (Image: Peggy Peterson)

The NFT features a one-minute 3D animation of the type of modified mRNA that protects the immune system from SARS-CoV-2 and the platform technology that holds promise for combatting other infectious diseases, as well as immunotherapeutics, cancer treatments, genetic diseases, and more. The video shows mRNA encapsulated inside of lipid nanoparticles, the fat droplets that are the delivery technique Weissman's lab applied to ensure mRNA reaches the right part of the body to trigger an immune response. The NFT also includes Penn mRNA patent documents and a letter from Weissman, who directs the Penn Institute for RNA Innovation, about the ways in which he and colleagues are leveraging the mRNA technology platform to fight not only coronaviruses but also influenza, herpes, malaria, sickle cell anemia, and cancer.

Funds raised by the sale of the NFT-the first digital asset Penn has offered-will further important research across the university.

'The stunning speed with which the mRNA COVID-19 vaccines were developed and their global success in fighting the pandemic has led to an explosion of interest in how modified mRNA technology can be applied across many fields of medicine,' said J. Larry Jameson, executive vice president of the University of Pennsylvania for the Health System and dean of the Perelman School of Medicine. 'Dr. Weissman and his colleagues across Penn are continuing to chart new paths of discovery with the potential for global impact. This digital asset celebrates their historic scientific achievements and points to a bright future in vaccine research and development.'

A non-fungible token, or NFT, is a unit of data stored on a blockchain, which is a database of transactions of digital currencies or assets that are authenticated and tracked. Penn joins a small number of universities to mint NFTs as a way to further support research and education. The development of the NFT celebrating mRNA discoveries was led by the Wharton School's Stevens Center for Innovation in Finance, which includes a Blockchain Laboratory, in collaboration with Penn Medicine and the Penn Center for Innovation, the university's hub for technology commercialization and entrepreneurship.

The auction for The University of Pennsylvania mRNA NFT: Vaccines for a New Era will be offered exclusively online by Christie's between July 15 and July 25.

Editor's note: The Pfizer/BioNTech and Moderna COVID-19 mRNA vaccines both use licensed University of Pennsylvania technology. As a result of these licensing relationships, Penn, Dr. Weissman and Dr. Kariko have received, and may continue to receive, significant financial benefits based on the sale of these products. BioNTech also provides ongoing sponsored research funding for Dr. Weissman's research into the development of infectious disease vaccines.

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -2.91% 147.61 Delayed Quote.-42.74%
PFIZER, INC. -1.40% 48.58 Delayed Quote.-17.73%
All news about BIONTECH SE
08/17European ADRs Move Lower in Wednesday Trading
08/17The market got ahead of itself on retailers' earnings
08/17The market got ahead of itself on retailers' earnings
08/16Ending Covid-19 Pandemic ? and Preventing Worse Ones - Demands Equity, Innovation, Inve..
08/10HC Wainwright Lowers BioNTech SE's Price Target to $272 From $283, Maintains Buy Rating
08/09European ADRs Move Higher in Tuesday Trading
08/09Goldman Sachs Cuts BioNTech SE's Price Target to $200 From $209, Keeps Neutral Rating
08/09BIONTECH : Berenberg reiterates its Buy rating
08/09BIONTECH : Buy rating from Berenberg
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Sales 2022 16 450 M 16 675 M 16 675 M
Net income 2022 8 659 M 8 777 M 8 777 M
Net cash 2022 10 768 M 10 915 M 10 915 M
P/E ratio 2022 4,32x
Yield 2022 -
Capitalization 35 388 M 35 872 M 35 872 M
EV / Sales 2022 1,50x
EV / Sales 2023 1,05x
Nbr of Employees 3 082
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 145,62 €
Average target price 219,73 €
Spread / Average Target 50,9%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-42.74%36 949
WUXI APPTEC CO., LTD.-23.44%39 407
GENMAB A/S0.99%23 720